What if a shot designed to stop a rash could also slash the odds of dying from a heart attack? A new analysis of 246,822 U.S. adults with atherosclerotic heart disease found that those who received the recombinant shingles vaccine had a 66% lower rate of all-cause mortality and a 46% reduction in major adverse cardiac events within one year.
The matched cohort—123,411 vaccinated and 123,411 unvaccinated—was drawn from TriNetX, a large database containing medical records from millions of Americans. After adjustment for age, sex, medications, and socio-economic factors, vaccinated participants also experienced 32% fewer heart attacks, 25% fewer strokes, and 25% fewer heart-failure events.
Dr. Robert Nguyen, the study’s lead author, said:
"This vaccine has been found over and over again to have cardioprotective effects for reducing heart attack, stroke and death."
The biology may hinge on herpes zoster re-activation, which can trigger a clotting cascade and vascular inflammation. By preventing shingles, the vaccine appears to interrupt this process, though the exact pathway remains under investigation.
Investigators presented the findings at the American College of Cardiology’s ACC.26 scientific sessions. They emphasized that the observational design leaves room for residual healthy-user bias, despite rigorous matching. Follow-up was limited to 12 months, and the cohort already carried high baseline cardiovascular risk.
Dr. Nguyen added:
"Vaccines are one of the most important medicines we have to prevent disease. Sometimes patients are unsure about whether they should get a vaccine or not, particularly in an age of disinformation. These results provide another reason for them to elect to get the vaccine."
Current CDC guidelines recommend two doses of the recombinant shingles vaccine for everyone starting at age 50, regardless of prior shingles or live-vaccine history. The new data do not alter those recommendations, but they may prompt clinicians to prioritize the shot in patients with established coronary artery disease.
Experts caution that randomized trials are still needed before changing clinical practice. The observed benefits, while large, apply to a high-risk cohort and should not be generalized to younger or healthier populations.
⚠️ LEGAL DISCLAIMER: It is for informational purposes only. It never substitutes for professional medical advice, diagnosis, or treatment. Always consult your doctor regarding any questions about your health.
Source: Sciencedaily